Abstract
Introduction
Stage II–III rectal cancer requires multidisciplinary cancer care, and adolescents and young adults (AYA, ages 15–39 years) often do not receive optimal cancer therapy.
Methods
Overall, 3295 AYAs with clinical stage II–III rectal cancer were identified in the National Cancer Database. Factors associated with the receipt of adjuvant and surgical therapies, as well as overall survival (OS), were examined.
Results
The majority of patients were non-Hispanic White (72.0 %), male (57.5 %), and without comorbidities (93.8 %). A greater proportion of Black and Hispanic patients did not receive radiation (24.5 and 27.1 %, respectively, vs. 16.5 % for non-Hispanic White patients), surgery (22.4 % and 21.6 vs. 12.3 %), or chemotherapy (21.5 % and 24.1 vs. 14.7 %) compared with non-Hispanic White patients (all p < 0.05). After controlling for competing factors, Black (odds ratio [OR] 0.7, 95 % confidence interval [CI] 0.5–0.9) and Hispanic patients (OR 0.6, 95 % CI 0.4–0.9) were less likely to receive neoadjuvant chemoradiation compared with non-Hispanic White patients. Females, the uninsured, and those treated at a community cancer center were also less likely to receive neoadjuvant therapy. Having government insurance (OR 0.22, 95 % CI 010–0.49) was a predictor for not receiving surgery. Although 5-year OS was lower (p < 0.05) in Black (59.8 %) and Hispanic patients (65.9 %) compared with non-Hispanic White patients (74.9 %), on multivariate analysis race did not impact mortality. Not having surgery (hazard ratio [HR] 7.1, 95 % CI 2.8–18.2) had the greatest influence on mortality, followed by poorly differentiated histology (HR 3.0, 95 % CI 1.3–6.5), nodal positivity (HR 2.6, 95 % CI 1.9–3.6), no chemotherapy (HR 1.9, 95 % CI 1.03–3.6), no insurance (HR 1.7, 95 % CI 1.1–2.7), and male sex (HR 1.5, 95 % CI 1.1–2.0).
Conclusion
There are racial and socioeconomic disparities in the treatment of stage II–III rectal cancer in AYAs, many of which impact OS. Interventions that can address and mitigate these differences may lead to improvements in OS for some patients.
Similar content being viewed by others
References
Shapiro NL, Bhattacharyya N. Population-based outcomes for pediatric thyroid carcinoma. Laryngoscope. 2005;115:337–40.
Singh KE, Taylor TH, Pan CG, Stamos MJ, Zell JA. Colorectal cancer incidence among young adults in California. J Adolesc Young Adult Oncol. 2014;3:176–84.
Bailey CE, Hu CY, You YN, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 2015;150:17–22.
Nass SJ, Beaupin LK, Demark-Wahnefried W, et al. Identifying and addressing the needs of adolescents and young adults with cancer: summary of an Institute of Medicine workshop. Oncologist. 2015;20:186–95.
Bleyer A. Young adult oncology: the patients and their survival challenges. CA Cancer J Clin. 2007;57:242–55.
Thomas DM, Seymour JF, O’Brien T, Sawyer SM, Ashley DM. Adolescent and young adult cancer: a revolution in evolution?. Intern Med J. 2006;36:302–07.
<20101222094132964.pdf > .
Bleyer A, Budd T, Montello M. Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer. 2006;107:1645–55.
Albritton K, Bleyer WA. The management of cancer in the older adolescent. Eur J Cancer. 2003;39:2584–99.
Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774–80.
Sabounchi S, Keihanian S, Anand BS. Impact of race on colorectal cancer. Clin Colorectal Cancer. 2012;11:66–70.
Krieger N, Quesenberry C Jr, Peng T, et al. Social class, race/ethnicity, and incidence of breast, cervix, colon, lung, and prostate cancer among Asian, Black, Hispanic, and White residents of the San Francisco Bay Area, 1988–92 (United States). Cancer Causes Control. 1999;10:525–37.
Pahlman L, Glimelius B. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med. 1997;336:980–7.
Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U, et al. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644–50.
Roh MS, Colangelo LH, O’Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27:5124–30.
Albano JD, Ward E, Jemal A, et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst. 2007;99:1384–94.
Hao Y, Jemal A, Zhang X, Ward EM. Trends in colorectal cancer incidence rates by age, race/ethnicity, and indices of access to medical care, 1995–2004 (United States). Cancer Causes Control. 2009;20:1855–63.
Berry J, Bumpers K, Ogunlade V, et al. Examining racial disparities in colorectal cancer care. J Psychosoc Oncol. 2009;27:59–83.
Polite BN, Dignam JJ, Olopade OI. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol. 2006;24:2179–87.
Pacini F, Schlumberger M, Harmer C, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol. 2005;153:651–59.
Williams RT, Stewart AK, Winchester DP. Monitoring the delivery of cancer care: Commission on Cancer and National Cancer Data Base. Surg Oncol Clin N Am. 2012;21:377–88.
Yin D, Morris C, Allen M, Cress R, Bates J, Liu L, et al. Does socioeconomic disparity in cancer incidence vary across racial/ethnic groups? Cancer Causes Control. 2010;21:1721–30.
Glanz K, Croyle RT, Chollette VY, Pinn VW. Cancer-related health disparities in women. Am J Public Health. 2003;93:292–8.
Gross CP, Smith BD, Wolf E, Andersen M. Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002? Cancer. 2008;112:900–8.
Wheeler SB, Reeder-Hayes KE, Carey LA. Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research. Oncologist. 2013;18:986–93.
Kish JK, Yu M, Percy-Laurry A, Altekruse SF. Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in Surveillance, Epidemiology, and End Results (SEER) Registries. J Natl Cancer Inst Monogr. 2014;2014:236–43.
Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78–93.
Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.
Author Contributions
Study conception and design: Drs. Lee, Attaluri, McLemore, Stern, Bilchik, and Goldfarb. Acquisition of data: Drs. Lee, Teng, Pederson, and Tavangari. Analysis and interpretation of data: Drs. Lee, Teng, Pederson, Tavangari, Stern, Bilchik, and Goldfarb. Drafting of the manuscript: Drs. Lee, Teng, Pederson, Tavangari, and Goldfarb. Critical revision: Drs. Attaluri, McLemore, Bilchik, and Goldfarb.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The data used in the study are derived from a de-identified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data by the investigator.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Lee, D.Y., Teng, A., Pedersen, R.C. et al. Racial and Socioeconomic Treatment Disparities in Adolescents and Young Adults with Stage II–III Rectal Cancer. Ann Surg Oncol 24, 311–318 (2017). https://doi.org/10.1245/s10434-016-5626-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-016-5626-0